mRNA therapeutics: fast-to-market strategies
"This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of &q...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boca Raton ; London ; New York
CRC Press, Taylor Francis Group
2022
|
| Ausgabe: | First edition |
| Schlagworte: | |
| Online-Zugang: | TUM01 |
| Zusammenfassung: | "This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented to secure fast approval of copies of mRNA vaccines. Projections of financial plans to establish RNA manufacturing facilities are provided, along with details of supply chain management. Finally, the future of nucleic acid products in gene therapy and other newer applications is presented, along with a perspective that all new vaccines will be the nucleic acid type that will further provide first-time prevention of autoimmune disorders. It is projected that both big pharma and startups will enter this field, and we can expect significant additions to our drug armamentarium soon"-- |
| Beschreibung: | 1 Online-Ressource Illustrationen, Diagramme |
| ISBN: | 9781003248156 |
Internformat
MARC
| LEADER | 00000nmm a22000008c 4500 | ||
|---|---|---|---|
| 001 | BV048636548 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 230109s2022 |||| o||u| ||||||eng d | ||
| 020 | |a 9781003248156 |9 978-1-003-24815-6 | ||
| 024 | 7 | |a 10.1201/9781003248156 |2 doi | |
| 035 | |a (OCoLC)1357537401 | ||
| 035 | |a (DE-599)BVBBV048636548 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91G | ||
| 084 | |a VS 9400 |0 (DE-625)147728:253 |2 rvk | ||
| 084 | |a CIT 840 |2 stub | ||
| 084 | |a CHE 860 |2 stub | ||
| 084 | |a MED 970 |2 stub | ||
| 100 | 1 | |a Niazi, Sarfaraz Khan |d 1949- |e Verfasser |0 (DE-588)133089851 |4 aut | |
| 245 | 1 | 0 | |a mRNA therapeutics |b fast-to-market strategies |c Sarfaraz K. Niazi |
| 250 | |a First edition | ||
| 264 | 1 | |a Boca Raton ; London ; New York |b CRC Press, Taylor Francis Group |c 2022 | |
| 300 | |a 1 Online-Ressource |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 505 | 8 | |a The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance | |
| 520 | 3 | |a "This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented to secure fast approval of copies of mRNA vaccines. Projections of financial plans to establish RNA manufacturing facilities are provided, along with details of supply chain management. Finally, the future of nucleic acid products in gene therapy and other newer applications is presented, along with a perspective that all new vaccines will be the nucleic acid type that will further provide first-time prevention of autoimmune disorders. It is projected that both big pharma and startups will enter this field, and we can expect significant additions to our drug armamentarium soon"-- | |
| 653 | 0 | |a mRNA vaccines | |
| 653 | 0 | |a Drug development | |
| 653 | 0 | |a Pharmaceutical technology | |
| 653 | 0 | |a mRNA Vaccines / standards | |
| 653 | 0 | |a Drug Development / standards | |
| 653 | 0 | |a Technology, Pharmaceutical / methods | |
| 653 | 0 | |a RNA, Messenger / therapeutic use | |
| 653 | 0 | |a MEDICAL / Pharmacology | |
| 653 | 0 | |a MEDICAL / Biochemistry | |
| 653 | 0 | |a MEDICAL / Infectious Diseases | |
| 653 | 0 | |a Drug development | |
| 653 | 0 | |a mRNA vaccines | |
| 653 | 0 | |a Pharmaceutical technology | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-1-03-216344-4 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 978-1-03-216348-2 |
| 912 | |a ZDB-30-PQE | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034011537 | ||
| 966 | e | |u https://ebookcentral.proquest.com/lib/munchentech/detail.action?docID=7121420 |l TUM01 |p ZDB-30-PQE |q TUM_Einzelkauf_2023 |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804184773851086848 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Niazi, Sarfaraz Khan 1949- |
| author_GND | (DE-588)133089851 |
| author_facet | Niazi, Sarfaraz Khan 1949- |
| author_role | aut |
| author_sort | Niazi, Sarfaraz Khan 1949- |
| author_variant | s k n sk skn |
| building | Verbundindex |
| bvnumber | BV048636548 |
| classification_rvk | VS 9400 |
| classification_tum | CIT 840 CHE 860 MED 970 |
| collection | ZDB-30-PQE |
| contents | The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance |
| ctrlnum | (OCoLC)1357537401 (DE-599)BVBBV048636548 |
| discipline | Chemie / Pharmazie Chemie Chemie-Ingenieurwesen Medizin |
| discipline_str_mv | Chemie / Pharmazie Chemie Chemie-Ingenieurwesen Medizin |
| edition | First edition |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03007nmm a22005538c 4500</leader><controlfield tag="001">BV048636548</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">230109s2022 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781003248156</subfield><subfield code="9">978-1-003-24815-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1201/9781003248156</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1357537401</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048636548</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91G</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9400</subfield><subfield code="0">(DE-625)147728:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CIT 840</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 860</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 970</subfield><subfield code="2">stub</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Niazi, Sarfaraz Khan</subfield><subfield code="d">1949-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)133089851</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">mRNA therapeutics</subfield><subfield code="b">fast-to-market strategies</subfield><subfield code="c">Sarfaraz K. Niazi</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boca Raton ; London ; New York</subfield><subfield code="b">CRC Press, Taylor Francis Group</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">"This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented to secure fast approval of copies of mRNA vaccines. Projections of financial plans to establish RNA manufacturing facilities are provided, along with details of supply chain management. Finally, the future of nucleic acid products in gene therapy and other newer applications is presented, along with a perspective that all new vaccines will be the nucleic acid type that will further provide first-time prevention of autoimmune disorders. It is projected that both big pharma and startups will enter this field, and we can expect significant additions to our drug armamentarium soon"--</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">mRNA vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Drug development</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">mRNA Vaccines / standards</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Drug Development / standards</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Technology, Pharmaceutical / methods</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">RNA, Messenger / therapeutic use</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">MEDICAL / Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">MEDICAL / Biochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">MEDICAL / Infectious Diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Drug development</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">mRNA vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical technology</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-1-03-216344-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">978-1-03-216348-2</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PQE</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034011537</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://ebookcentral.proquest.com/lib/munchentech/detail.action?docID=7121420</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-30-PQE</subfield><subfield code="q">TUM_Einzelkauf_2023</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV048636548 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T21:16:46Z |
| indexdate | 2024-07-10T09:44:40Z |
| institution | BVB |
| isbn | 9781003248156 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034011537 |
| oclc_num | 1357537401 |
| open_access_boolean | |
| owner | DE-91G DE-BY-TUM |
| owner_facet | DE-91G DE-BY-TUM |
| physical | 1 Online-Ressource Illustrationen, Diagramme |
| psigel | ZDB-30-PQE ZDB-30-PQE TUM_Einzelkauf_2023 |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | CRC Press, Taylor Francis Group |
| record_format | marc |
| spelling | Niazi, Sarfaraz Khan 1949- Verfasser (DE-588)133089851 aut mRNA therapeutics fast-to-market strategies Sarfaraz K. Niazi First edition Boca Raton ; London ; New York CRC Press, Taylor Francis Group 2022 1 Online-Ressource Illustrationen, Diagramme txt rdacontent c rdamedia cr rdacarrier The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance "This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented to secure fast approval of copies of mRNA vaccines. Projections of financial plans to establish RNA manufacturing facilities are provided, along with details of supply chain management. Finally, the future of nucleic acid products in gene therapy and other newer applications is presented, along with a perspective that all new vaccines will be the nucleic acid type that will further provide first-time prevention of autoimmune disorders. It is projected that both big pharma and startups will enter this field, and we can expect significant additions to our drug armamentarium soon"-- mRNA vaccines Drug development Pharmaceutical technology mRNA Vaccines / standards Drug Development / standards Technology, Pharmaceutical / methods RNA, Messenger / therapeutic use MEDICAL / Pharmacology MEDICAL / Biochemistry MEDICAL / Infectious Diseases Erscheint auch als Druck-Ausgabe, Hardcover 978-1-03-216344-4 Erscheint auch als Druck-Ausgabe, Paperback 978-1-03-216348-2 |
| spellingShingle | Niazi, Sarfaraz Khan 1949- mRNA therapeutics fast-to-market strategies The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance |
| title | mRNA therapeutics fast-to-market strategies |
| title_auth | mRNA therapeutics fast-to-market strategies |
| title_exact_search | mRNA therapeutics fast-to-market strategies |
| title_exact_search_txtP | mRNA therapeutics fast-to-market strategies |
| title_full | mRNA therapeutics fast-to-market strategies Sarfaraz K. Niazi |
| title_fullStr | mRNA therapeutics fast-to-market strategies Sarfaraz K. Niazi |
| title_full_unstemmed | mRNA therapeutics fast-to-market strategies Sarfaraz K. Niazi |
| title_short | mRNA therapeutics |
| title_sort | mrna therapeutics fast to market strategies |
| title_sub | fast-to-market strategies |
| work_keys_str_mv | AT niazisarfarazkhan mrnatherapeuticsfasttomarketstrategies |